Abstract: Disclosed is a composition for treating a neurological disease caused by nerve injury, including an isolated polynucleotide of a 5?-untranslated region (5?UTR) of a Gpr151 gene or a variant thereof. Also disclosed are a novel variant polynucleotide of 5?UTR of a Gpr151 gene and a vector including the polynucleotide.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

Abstract: The present inventors confirmed that when a brazzein expression recombinant vector for high expression of brazzein in Saccharomyces cerevisiae was prepared and a S. cerevisiae strain Y2805 was transformed with the recombinant vector, the expression level of brazzein was particularly high, thereby completing an optimal expression system for mass-producing brazzein. Further, when the brazzein expression system is cultured under the optimal culture conditions according to the present invention, the amount of brazzein produced is further increased, the purification process is simple, and costs are reduced. Therefore, it is expected that the brazzein expression system according to the present invention can be widely used for mass-producing and commercializing brazzein, which is a sweet protein.

Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

Abstract: In some aspects, the disclosure relates to recombinant adeno-associated viruses (rAAVs) comprising a nucleic acid encoding a fusion protein comprising a DNA-binding domain and a transcriptional regulator domain and methods of using the same. In some embodiments, expression of the fusion protein results in modified expression of a target gene in a cell.

Abstract: Embodiments disclosed herein include novel nucleic acid-guided nucleases, novel guide nucleic acids, and novel targetable nuclease systems, and methods of use. In some embodiments, engineered non-naturally occurring nucleic acid-guided nucleases, can be used with known guide nucleic acids in a targetable nuclease system. In certain embodiments, targetable nuclease systems can be used to edit targeted genomes of humans and other species. In some embodiments, methods include, but are not limited to, recursive genetic engineering and trackable genetic engineering methods.

Abstract: The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.

Abstract: The invention relates to a method for monitoring the treatment of a subject undergoing therapy with an active that is naltrexone or a metabolite or analogue thereof, comprising: measuring the gene expression profile of any of the genes listed in Table 1 or Table 2, in a sample of CD3+ cells obtained from the subject undergoing treatment; wherein if the expression of any of the genes in Table 1 is increased compared to a control, or if any of the genes listed in Table 2 is decreased compared to a control the active is being administered at an effective level.

Abstract: Methods are provided for conducting a dual-probe assay on a set of nucleic acid targets, including: combining a set of dual probes with a sample composition potentially comprising a set of nucleic acid targets to form a set of cleavable ternary nucleic acid complexes; releasing from the cleavable ternary nucleic acid complex a set of recognition element fragments; hybridizing each of the set of released recognition element fragments to a coded oligonucleotide probe and using resulting hybridized released recognition elements as primers for copying the coded oligonucleotide probe to produce a sect of target-associated codes, wherein each of the coded oligonucleotide probes comprises a code from a set of codes, each code comprises at least one segment encoding one or more symbols that correspond to a sequence of one or more nucleotides; and performing a detection event to identify a set of detected codes of the target-associated codes.

Abstract: Disclosed are systems and methods that include and utilize engineered riboregulated switchable feedback promoters (rSFPs). The disclosed systems and methods include and utilize as a component one or more expression cassettes. At least one expression cassette of the disclosed systems and methods comprises a promoter operably linked to DNA encoding an RNA switch located 3? of the promoter and a target gene or operon located 3? of the DNA encoding the RNA switch, where the RNA switch regulates expression of the target gene. Suitable promoters may include stress responsive promoters. The disclosed systems and methods may include and utilize a second expression cassette that includes an inducible promoter for expressing an RNA effector of the RNA switch in the first expression cassette.

Abstract: The present invention provides a DNA-targeting RNA comprising a single-guide RNA (sgRNA) and a ribonucleotide sequence rich in adenine ribonucleotide, and its use in gene editing, and a method for improving the efficiency of sgRNA-mediated gene editing, comprising a step of adding a ribonucleotide sequence rich in adenine ribonucleotide at 3? end of the sgRNA.

Abstract: An object is to provide a versatile means utilizing a probe for dPCR, which enables quick detection of a mutation relevant to a cancer. A library including a plurality of probes and/or primers or primer pairs for detecting a mutation relevant to a cancer in the DNA-binding domain of the TP53 gene is provided. By using the present invention, relapse of alimentary canal cancer after treatment can be diagnosed at an early stage. Individualized post-treatment follow-up of an alimentary canal cancer patient is also enabled.

Abstract: An improved promoter and a use thereof. An improvement is to mutate a nucleic acid sequence between ?35 region and ?10 region in a promoter region into recognition sites for an endonuclease. The improvement can overcome the problem that a strong promoter in a vector based on blue-white screening initiates the transcription or translation of foreign genes and a transcription or translation product might be toxic to a host and cannot be cloned, avoid the deficiency that frameshift mutation of a gene due to a lack of 1-2 bp of the vector at digestion sites results in false positive clones, and eliminate a false negative phenomenon that a plate is rich in blue spots due to a small fragment of foreign DNA and a reading frame of the gene which is unchanged by inserting the foreign DNA.

Abstract: Monodisperse structures with precise numbers of polymer arms and oligonucleotide chains conjugated to a backbone are disclosed. The structures, referred to miktoarm conjugates, are resistant to nuclease degradation and are capable of regulating gene expression in the absence of a co-carrier.

Abstract: The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element.” In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element,” but include at least a portion of a bacterial origin of replication.

Abstract: The present invention relates to a polypeptide that forms one part of a two-part linker in which the polypeptide spontaneously forms an isopeptide bond with a peptide tag, the second part of the two-part linker. Nucleic acid molecules encoding the polypeptide, vectors comprising said nucleic acid molecules, and host cells comprising said vectors and nucleic acid molecules are also provided. A kit comprising said two-part linker (i.e. peptide tag and polypeptide binding partner), and/or nucleic acid molecules/vectors is also provided. A method of producing the polypeptide (binding partner) and the uses of the polypeptide of the invention are also provided.

Abstract: Herein is reported a method for producing C-terminally biotinylated FcRn comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding FcRn and E. coli biotin-[acetyl-CoA-carboxylase] ligase (BirA) in a biotin containing medium, and recovering C-terminally biotinylated FcRn from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding FcRn and E. coli BirA is stably integrated into the genome of the mammalian cell and comprises in 5?- to 3?-direction a first expression cassette encoding class I major histocompatibility complex-like protein (?-FcRn) comprising a HisAvi-tag at the C-terminus, a second expression cassette encoding ?2-microglobulin (?2m), a third expression cassette encoding class I major histocompatibility complex-like protein (?-FcRn) comprising a HisAvi-tag at the C-terminus, a fourth expression cassette encoding ?2-microglobulin (?2m), and a fifth expression cassette encoding E. coli biotin-[acetyl-CoA-carboxylase] ligase.

Abstract: Methods are provided for conducting an assay on a set of nucleic acid targets, including: combining a set of dual probes with a sample composition potentially comprising a set of nucleic acid targets to form a set of cleavable ternary nucleic acid complexes; releasing from the cleavable ternary nucleic acid complex a set of recognition element fragments comprising the recognition element sequence; combining the released recognition element fragments with an additional nucleic acid sequence from a set of additional nucleic acid sequences to create a circular nucleic acid, wherein the circular nucleic acid comprises a target-associated code and additional sequence elements; and performing a detection event to identify a set of detected codes of the target-associated codes.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.